Pulse Biosciences, Inc. (PLSE) |
| 26.29 -0.95 (-3.49%) 07-10 16:00 |
| Open: | 27.06 |
| High: | 27.2 |
| Low: | 25.87 |
| Volume: | 257,581 |
| Market Cap: | 1,820(M) |
| PE Ratio: | -23.9 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 31.00 |
| Resistance 1: | 28.43 |
| Pivot price: | 27.47 |
| Support 1: | 24.27 |
| Support 2: | 20.19 |
| 52w High: | 31 |
| 52w Low: | 12.56 |
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
| EPS | -76400000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -4.00 |
| Return on Assets (ttm) | 775.6 |
| Return on Equity (ttm) | -45.0 |
Wed, 01 Jul 2026
Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative? - Sahm
Wed, 01 Jul 2026
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Wed, 01 Jul 2026
PLSE Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 24 Jun 2026
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth - Moomoo
Mon, 22 Jun 2026
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting? - simplywall.st
Mon, 15 Jun 2026
Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |